The common shares of this small company appreciated an astounding 1,064% in the past 12 months. Following such a showing, it would be easy to dismiss the equity as "overbought," expensive, and unworthy of any serious consideration as a potential addition to one's portfolio. It's not that simple when it comes to the biopharmaceutical sector, however, as the record shows that eye-popping historical percentage gains don't necessarily preclude additional compelling returns in the future. This assessment certainly applies to MannKind (NASDAQ:MNKD) and Keryx Biopharm. (NASDAQ:KERX), both of which we've recommended in recent months. The company whose shares performed so incredibly well is ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) and we think the biotech's research and development...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|